Integra LifeSciences Holdings (IART)

Debt-to-equity ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	1,087,920	1,132,290	1,723,380	1,742,020	1,395,820	1,419,620	1,333,410	1,337,210	1,300,490	1,381,140	1,385,540	1,389,930	1,388,680	1,387,430	1,386,180	1,484,910	1,408,220	1,414,000	1,472,320	1,478,190
Total stockholders’ equity	US$ in thousands	1,545,280	1,521,590	1,534,200	1,597,950	1,587,880	1,579,220	1,683,160	1,674,940	1,804,400	1,724,410	1,660,920	1,615,200	1,684,800	1,631,690	1,574,980	1,529,330	1,514,870	1,397,990	1,349,100	1,341,800
Debt-to-equity ratio		0.70	0.74	1.12	1.09	0.88	0.90	0.79	0.80	0.72	0.80	0.83	0.86	0.82	0.85	0.88	0.97	0.93	1.01	1.09	1.10

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,087,920K ÷ $1,545,280K
= 0.70

The debt-to-equity ratio of Integra LifeSciences Holdings has been fluctuating over the years, indicating varying levels of leverage in the company's capital structure. From March 31, 2020, to December 31, 2024, the ratio ranged from a high of 1.12 to a low of 0.70.

A high debt-to-equity ratio suggests that the company is relying more on debt to finance its operations, which can increase financial risk. Conversely, a low ratio implies a conservative approach with more reliance on equity financing.

Overall, the decreasing trend in the debt-to-equity ratio from 1.10 in March 2020 to 0.70 in December 2024 indicates a potential shift towards a more equity-based capital structure, which may signal improved financial stability and lower risk for the company. However, it is essential to consider other financial metrics and factors to gain a comprehensive understanding of Integra LifeSciences Holdings' financial health and performance.